DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Carimune NF (Immune Globulin Intravenous (Human)) - Drug Interactions, Contraindications, Overdosage, etc



CARIMUNE NF drug label information in our database does not contain a dedicated section on drug interactions. Please check subsections of WARNINGS AND PRECAUTIONS as well as other sources.


As with all blood products containing IgA, Immune Globulin Intravenous (Human), Carimune™ NF, is contra-indicated in patients with selective IgA deficiency, who possess antibody to IgA. It may also be contraindicated in patients who have had severe systemic reactions to the intravenous or intramuscular administration of human immune globulin.


  1. Gardi A: Quality control in the production of an immunoglobulin for intravenous use. Blut 1984; 48:337-344.
  2. Römer J, Morgenthaler JJ, Scherz R, et al: Characterization of various immunoglobulin-preparations for intravenous application. I. Protein composition and antibody content. Vox Sang 1982; 42:62-73.
  3. Römer J, Späth PJ, Skvaril F, et al: Characterization of various immunoglobulin preparations for intravenous application. II. Complement activation and binding to Staphylococcus protein A. Vox Sang 1982; 42:74-80.
  4. Omar A, and Kempf C: Removal of neutralized model Parvoviruses and Enteroviruses in human IgG solutions by nanofiltration. Transfusion, in press (2002).
  5. Späth P, Kempf C, and Gold R: Herstellung, Verträglichkeit und Virussicherheit von intravenösem Immunglobulin. In [laquo ]Immunglobuline in der Neurobiologie[raquo ] (P. Berlit, ed.), Steinkopff Verlag, Darmstadt, BRD, 2001, pp 1-42.
  6. Kempf C, Morgenthaler JJ, Rentsch M, and Omar A: Viral safety and manufacturing of an intravenous immunoglobulin. In [laquo ]Intravenous Immunoglobulin Research and Therapy[raquo ] Kazatchkine and Morell, eds. Parthenon Publishing Group. 1996, pp. 11-18.
  7. Römer J, Späth PJ: Molecular composition of immunoglobulin preparations and its relation to complement activation, in Nydegger UE (ed): Immunohemotherapy: A Guide to Immunoglobulin Prophylaxis and Therapy. London, Academic Press, 1981, pp 123-130.
  8. Skvaril F, Roth-Wicky B, and Barandun S: IgG subclasses in human-g-globulin preparations for intravenous use and their reactivity with Staphylococcus protein A. Vox Sang 1980; 38:147.
  9. Skvaril F: Qualitative and quantitative aspects of IgG subclasses in i.v. immunoglobulin preparations, in Nydegger UE (ed): Immunohemotherapy: A Guide to Immunoglobulin Prophylaxis and Therapy. London, Academic Press, 1981, pp 113-122.
  10. Skvaril F, and Barandun S: In vitro characterization of immunoglobulins for intravenous use, in Alving BM, Finlayson JS (eds): Immunoglobulins: Characteristics and Uses of Intravenous Preparations, DHHS Publication No. (FDA)-80-9005. US Government Printing Office, 1980, pp 201-206.
  11. Burckhardt JJ, Gardi A, Oxelius V, et al: Immunoglobulin G subclass distribution in three human intravenous immunoglobulin preparations. Vox Sang 1989; 57:10-14.
  12. Morell A, and Skvaril F: Struktur und biologische Eigenschaften von Immunoglobulinen und g-Globulin-Präparaten. II. Eigenschaften von g-Globulin-Präparaten. Schweiz Med Wochenschr 1980; 110:80.
  13. Morell A, Schürch B, Ryser D, et al: In vivo behaviour of gamma globulin preparations. Vox Sang 1980; 38:272.
  14. Imbach P, Barandun S, d'Apuzzo V, et al: High-dose intravenous gamma globulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981; 1:1228.
  15. Barandun S, Morell A, Skvaril F: Clinical experiences with immunoglobulin for intravenous use, in Alving BM, Finlayson JS (eds): Immunoglobulins: Characteristics and Uses of Intravenous Preparations. DHHS Publication No. (FDA)-80-9005. US Government Printing Office, 1980, pp 31-35.
  16. Schiff R, Sedlak D, Buckley R: Rapid infusion of Sandoglobulin® in patients with primary humoral immunodeficiency. J Allergy Clin Immunol, 88:61, 1991.
  17. Joller PW, Barandun S, Hitzig WH: Neue Möglichkeiten der Immunoglobulin-Ersatztherapie bei Antikörpermangel. Syndrom. Schweiz Med Wochenschr 1980; 110:1451.
  18. Barandun S, Imbach P, Morell A, et al: Clinical indications for immunoglobulin infusion, in Nydegger UE (ed): Immunohemotherapy: A Guide to Immunoglobulin Prophylaxis and Therapy. London, Academic Press, 1981, pp 275-282.
  19. Cunningham-Rundles C, Smithwick EM, Siegal FP, et al: Treatment of primary humoral immunodeficiency disease with intravenous (pH 4.0 treated) gamma globulin, in Nydegger UE (ed): Guide to Immunoglobulin Prophylaxis and Therapy. London, Academic Press, 1981, pp 283-290.
  20. Imbach P, Wagner HP, Berchtold W, et al: Intravenous immunoglobulin versus oral corticosteroids in acute immune thrombocytopenic purpura in childhood. Lancet 1985; 2:464.
  21. Fehr J, Hofmann V, Kappeler U: Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin. N Engl J Med 1982; 306:1254.
  22. Müller-Eckhardt C, Küenzlen E, Thilo-Körner D, et al: High-dose intravenous immunoglobulin for posttransfusion purpura. N Engl J Med 1983; 308:287.
  23. Wenske G, Gaedicke G, Küenzlen E, et al: Treatment of idiopathic thrombocytopenic purpura in pregnancy by high-dose intravenous immunoglobulin. Blut 1983; 46:347-353.
  24. Newland AC, Treleaven JG, Minchinton B, et al: High-dose intravenous IgG in adults with autoimmune thrombocytopenia. Lancet 1983; 1:84-87.
  25. Bussel JB, Kimberly RP, Inman RD, et al: Intravenous gammaglobulin for chronic idiopathic thrombocytopenic purpura. Blood 1983; 62:480-486.
  26. Abe T, Matsuda J, Kawasugi K, et al: Clinical effect of intravenous immunoglobulin in chronic idiopathic thrombocytopenic purpura. Blut 1983; 47:69-75.
  27. Bussel JB, Schulman I, Hilgartner MW, et al: Intravenous use of gamma globulin in the treatment of chronic immune thrombocytopenic purpura as a means to defer splenectomy. J Pediatr 1983; 103:651-654.
  28. Imholz B, et al: Intravenous immunoglobulin (i.v. IgG) for previously treated acute or for chronic idiopathic thrombocytopenic purpura (ITP) in childhood: A prospective multicenter study. Blut 1988; 56:63-68.
  29. Lusher JM, and Warrier I: Use of intravenous gamma globulin in children with idiopathic thrombocytopenic purpura and other immune thrombocytopenias. Am J Med 1987; 83 (suppl 4A):10-16.
  30. Winward DB, Brophy MT: Acute renal failure after administration of intravenous immunoglobulin: Review of the literature and case report. Pharmacotherapy 1995; 15: 765-772.
  31. Cant[uacute] TG, Hoehn-Saric EW, Burgess KM, Racusen L, Scheel P: Acute renal failure associated with immunoglobulin therapy. Am J. Kidney Dis. 1995; 25:228-234.
  32. Cayco AV, Perazelly Ma, Hayslett JP: Renal insufficiency after intravenous immune globulin therapy: A Report of Two Cases and an Analysis of the Literature. J. Amer. Soc Nephrology. 1997; 8:1788-1793.
  33. Rault R, Pirano B, Johston J, Oral A: Pulmonary and renal toxicity of intravenous immunoglobulin. Clin Nephrol: 1991, 36:83-86.
  34. Michail S, Nakopoulou L, Stravrianopoulos I, Stamatiadis D, Avdikou K, Vaiopoulos G, Stathakis C: Acute renal failure associated with immunoglobulin administration. Nephrol Dial Transpalant. 1997; 12:1497-99.
  35. Ashan N, Wiegand LA, Abendroth CS, Manning EC: Acute renal failure following immunoglobulin therapy. Am J Nephrol. 1996; 16:532-6.
  36. Hammarstrom L, and Smith CI: Placental transfer of intravenous immunoglobulin. Lancet 1986; 1:681.
  37. Sidiropoulos D, et al: Transplacental passage of intravenous immunoglobulin in the last trimester of pregnancy. J Pediatr 1986; 109:505-508.
  38. Wenske G, et al: Idiopathic thrombocytopenic purpura in pregnancy and neonatal period. Blut 1984; 48:377-382.
  39. Fabris P, et al: Successful treatment of a steroid-resistant form of idiopathic thrombocytopenic purpura in pregnancy with high doses of intravenous immunoglobulins. Acta Haemat 1987; 77:107-110.
  40. Coller BS, et al: Management of severe ITP during pregnancy with intravenous immunoglobulin (IVIgG). Clin Res 1985; 33:545A.
  41. Tchernia G, et al: Management of immune thrombocytopenia in pregnancy: Response to infusions of immunoglobulins. Am J Obstet Gynecol 1984; 148:225-226.
  42. Newland AC, et al: Intravenous IgG for autoimmune thrombocytopenia in pregnancy. N Engl J Med 1984; 310:261-262.
  43. Morgenstern GR, et al: Autoimmune thrombocytopenia in pregnancy: New approach to management. Br Med J 1983; 287:584.
  44. Ciccimarra F, et al: Treatment of neonatal passive immune thrombocytopenia. J Pediat 1984; 105:677-678.
  45. Rose VL, and Gordon LI: Idiopathic thrombocytopenic purpura in pregnancy. Successful management with immunoglobulin infusion. JAMA 1985; 254: 2626-2628.
  46. Gounder MP, et al: Intravenous gammaglobulin therapy in the management of a patient with idiopathic thrombocytopenic purpura and a warm autoimmune erythrocyte panagglutinin during pregnancy. Obstet Gynecol 1986; 67:741-746.
  47. Siber GR, Werner BG, Halsey NA, et al: Interference of immune globulin with measles and rubella immunisation. J. Pediatr. 1993; 122:204-211.
  48. American Academy of Pediatrics, Committee on Infectious Diseases: Recommended timing of routine measles immunization for children who have recently received immune globulin preparations. Pediatrics 1994; 93:682-685.
  49. Centers of Disease Control and Prevention Measles, mumps, and rubella-vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the advisory commitee on immunization practices (ACIP). MMWR, Morbidity and Mortality Weekly Report. May 22, 1998; vol 47/No. RR-8, 1-57.
  50. Phillips AO: Renal failure and intravenous immunoglobulin [letter; comment]. Clin Nephrol 1992; 36: 83-86.
  51. Cunningham-Rundles C, Day NK, Wahn V, et al: Reactions to intravenous gamma globulin infusions and immune complex formation, in Nydegger UE (ed): Immunohemotherapy: A Guide to Immunoglobulin Prophylaxis and Therapy. London, Academic Press, 1981, pp 447-449.
  52. Brox AG, Cournoyer D, et al: Hemolytic anemia following intravenous gamma globulin administration. Am J. Med. 1987; 82:633-635.
  53. Kim HC, Park CL, Cowan JH, et al: Massive intravascular hemolysis associated with intravenous immunoglobulin in bone marrow transplant recipients. Am J. Ped. Hematol/Oncol 1988; 10:67-74.
  54. Nicholls MD, Cummins JC, et al: Haemolysis induced by intravenously-administered immunoglobulin. Med J of Australia 1989; 150:404-406.
  55. Copelan EA et al: Hemolysis following intravenous immune globulin therapy. Transfusion 1986; 26:410-412.
  56. Aukrust P, Froland SS, N-B Liabakk, F. Müller, et al: Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood 1994; 84:2136-2143.
  57. Bagdasarian A, Tonetta S, Harel W, Mamidi R. Uemura Y: IVIG adverse reactions: potential role of cytokines and vasoactive substances. Vox Sang 1998; 74:74-82.
  58. Bussel JB, Pham LC, Hilgartner MW, et al: Long-term maintenance of adults with ITP using intravenous gamma globulin. Abstract, America Society of Hematology. New Orleans, December, 1985.
  59. Imbach PA, Kühne T, Holländer G: Immunologic aspects in the pathogenesis and treatment of immune thrombocytopenic purpura in children. Current opinion in Pediatrics 1997; 9:35-40.
  60. Anderson W, Bethea W: Renal lesions following administration of hypertonic solutions of sucrose. JAMA. 1940; 114:1983-1987.
  61. Lindberg H, Wald A: Renal lesions following the administration of hypertonic solutions: Arch Intern Med. 1939; 63:907-918.
  62. Rigdon RH, Cardwell ES: Renal lesions following the intravenous injection of hypertonic solution of sucrose: A clinical and experimental study. Arch Intern Med. 1942; 69:670-690.

Manufactured by:

ZLB Bioplasma AG

Wankdorfstrasse 10, 3000 Berne 22


US License No. 1598

Distributed by:

ZLB Bioplasma Inc.

Glendale, California 91203, USA

February 2003

R&W 02.03 20'000


-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017